跳至主要内容
临床试验/ACTRN12605000602628
ACTRN12605000602628招募中不适用

Evaluation of CF Patient Perception of Symptom Improvement Following Inhaled Antibiotic Treatment

Corus Pharma0 个研究点目标入组 15 人开始时间: 2005年10月5日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
6 Years 至 ot stated(—)
性别
All

入选标准

  • Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).

排除标准

  • 未提供

研究者

发起方
Corus Pharma

相似试验